Healthcare / Drug Manufacturers - Specialty & GenericNSE
$159.93
-2.69 (-1.65%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-799.8M · quality 59.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
254.8x
↑EV/EBITDA
14.4x
↑ROE
0.3%
↑Gross Margin
46.1%
↓Debt/Equity
0.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+8.1%
FCF CAGR
—
FCF margin
-10.9%
FCF / Net income
-28.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.64B · net income $6.2M · FCF $-178.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.64B | $1.64B | $1.51B | $1.65B | $1.30B |
| Net Income | $6.2M | $6.2M | $55.5M | $184.5M | $139.1M |
| EBITDA | $182.2M | $182.2M | $218.5M | $356.1M | $263.9M |
| EPS | 0.63 | 0.63 | 5.97 | 19.86 | 19.84 |
| Gross Margin | 46.1% | 46.1% | 45.6% | 50.3% | 52.7% |
| Operating Margin | 5.5% | 5.5% | 6.8% | 16.5% | 17.7% |
| Net Margin | 0.4% | 0.4% | 3.7% | 11.2% | 10.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.45 | 0.45 | 0.53 | 0.79 | 0.64 |
| Cash Flow | |||||
| Free Cash Flow | $-178.8M | $-178.8M | $-799.8M | $-886.7M | $-466.0M |
| Returns | |||||
| ROE | 0.3% | 0.3% | 2.7% | 15.0% | 16.8% |
| Valuation | |||||
| P/E | 254.79 | 254.79 | — | — | — |
| EV/EBITDA | 14.37 | 14.37 | — | — | — |
| P/B | 0.68 | 0.68 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 8.5% | 8.5% | -8.2% | 26.8% | — |
| EPS Growth | -89.5% | -89.5% | -69.9% | 0.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
182.8%
EPS terminal req.
$14.19
Spread vs growth
-272.2%
5Y implied EPS CAGR
93.8%
EPS terminal req.
$17.17
Spread vs growth
-183.3%
10Y implied EPS CAGR
46.0%
EPS terminal req.
$27.65
Spread vs growth
-135.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.3%
Start / end P/E
33.6x → 254.8x
EPS bridge
5.97 → 0.63
Residual
-588.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.